FrancophonIA/ELRC3.0 huggingface dataset:
English: The manufacture, import, possession, sale, supply and/or use of ZULVAC 8 BOVIS may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Estonian: ZULVAC 8 BOVISe tootmine, import, omamine, müük, tarnimine ja /või kasutamine on või võib olla teatud liikmesriikide territooriumil või osal nende territooriumist siseriiklike õigusaktide kohaselt keelatud.
English: After administration of a double dose, a slight and transient but significant increase in the mean rectal temperature of 0.7 ºC was recorded in the vaccinated calves during the first 24 hours.
Estonian: 24 tunni jooksul pärast kahekordse annuse manustamist täheldati vaktsineeritud vasikatel keskmise rektaaltemperatuuri väikest ja mööduvat, kuid olulist tõusu 0,7 °C.
English: PACKAGE LEAFLET FOR: ZULVAC 8 Bovis suspension for injection for cattle
Estonian: PAKENDI INFOLEHT ZULVAC 8 Bovis süstesuspensioon veistele
English: Name and address of the manufacturer responsible for batch release: Zoetis Manufacturing & Research Spain, S.L.
Estonian: Ravimipartii kasutamiseks vabastamise eest vastutava(te) tootja(te) nimi (nimed) ja aadress(id) Zoetis Manufacturing & Research Spain, S.L.
English: MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
Estonian: BIOLOOGILIS(T)E TOIMEAINE(TE) TOOTJA(D) JA RAVIMIPARTII KASUTAMISEKS VABASTAMISE EEST VASTUTAV(AD) TOOTJA(D)
English: Zoetis Finland Oy Tlf: +358 (0)9 4300 40
Estonian: Tlf: +358 (0)9 4300 40
English: After the second injection of a single dose, a slight and transient but significant increase in the mean rectal temperature of 0.4ºC was very commonly recorded in the vaccinated calves during the first 24 hours.
Estonian: Vaktsineeritud vasikatel täheldati väga sageli 24 tunni jooksul pärast teist ühe annuse süstimist kerget ja mööduvat keskmise rektaaltemperatuuri tõusu 0,4°C.
English: Zoetis Finland Oy Sími: +358 (0)9 4300 40
Estonian: Sími: +358 (0)9 4300 40
English: MARKETING AUTHORISATION HOLDER Zoetis Belgium SA
Estonian: MÜÜGILOA HOIDJA Zoetis Belgium SA
English: Suomi/Finland Zoetis Finland Oy Puh/Tel: +358 (0)9 4300 40
Estonian: Puh/Tel: +358 (0)9 4300 40
English: WITHDRAWAL PERIOD Withdrawal period: zero days
Estonian: Keeluaeg (-ajad)
English: Adjuvants:
Estonian: Süstevesi
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Vial label 100 ml
Estonian: 100 ml viaali silt
English: Strength Pharmaceutical Form
Estonian: Nimetus Tugevus Ravimvorm Loomali igid
English: Invented Name
Estonian: Pakendi sisu
English: • Symptomatic treatment of chronic pathological cognitive and neurosensorial impairment in elderly (excluding Alzheimer's disease and other dementia)
Estonian: • kroonilise patoloogilise kognitiivse ja neurosensoorse häire sümptomaatiline ravi (välja arvatud Alzheimeri tõbi ja dementsuse teised vormid) eakatel
English: • Ancillary treatment of Raynaud's syndrome
Estonian: • Raynaud'sündroomi lisaravi
English: All references to the above mentioned indications should be deleted from the remaining relevant sections of the summaries of product characteristics.
Estonian: Ravimi omaduste kokkuvõtt vastavates lõikudes tuleks kustutada kõik viited ülalmainitud näidustustele.
English: Patients who tolerate the first 90-minute infusion can receive subsequent infusions over 30 minutes.
Estonian: Patsiendid, kes taluvad esimest 90-minutilist infusiooni, võivad saada järgmised infusioonid 30-minutistena.
English: The full EPAR for Kadcyla can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Kadcyla kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Kadcyla is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Kadcyla võimalikult ohutu kasutamine.
English: Patients may remain on treatment unless the disease gets worse or unless they no longer tolerate treatment.
Estonian: Patsiendid võivad saada ravi, kuni haigus süveneb või kuni nad ravi enam ei talu.
English: What measures are being taken to ensure the safe and effective use of Kadcyla?
Estonian: Mis meetmed võetakse, et tagada Kadcyla ohutu ja efektiivne kasutamine?
English: Other information about Kadcyla
Estonian: Muu teave Kadcyla kohta
English: The European Commission granted a marketing authorisation valid throughout the European Union for Kadcyla on 15.11.2013.
Estonian: Euroopa Komisjon andis Kadcyla müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. novembril
English: The dose to be given depends on the patient's bodyweight and the infusion is repeated every 3 weeks.
Estonian: Annus sõltub patsiendi kehamassist ja infusiooni korratakse iga 3 nädala järel.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Kadcyla's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Kadcyla kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: In patients who develop allergic reactions or side effects, the treating doctor may have to reduce the dose or stop treatment with Kadcyla.
Estonian: Patsientidel, kellel tekivad allergilised reaktsioonid või kõrvalnähud, võib olla vaja annust vähendada või tuleb ravi Kadcylaga peatada.
English: Regarding Kadcyla's safety, overall side effects were considered to be manageable and the overall safety profile was considered favorable compared with other currently available medicines.
Estonian: Seoses Kadcyla ohutusega peeti üldisi kõrvalnähte juhitavaks ja üldist ohutusprofiili soodsaks võrreldes teiste olemasolevate ravimitega.
English: Patients should be observed during and after the infusion for any infusion-related reactions such as flushing, shivering fits and fever.
Estonian: Infusiooni ajal ja järel tuleb patsiente jälgida infusiooniga seotud reaktsioonide suhtes, näiteks õhetus, külmavärinad ja palavik.
English: What is Kadcyla and what is it used for?
Estonian: Mis on Kadcyla ja milleks seda kasutatakse?
English: Why is Kadcyla approved?
Estonian: Miks Kadcyla heaks kiideti?
English: Because of a potential risk of confusion between Kadcyla and Herceptin due to their similar sounding active substances (trastuzumab emtansine and trastuzumab) the company will provide educational material to all healthcare professionals expected to use Kadcyla or Herceptin to alert them not to use these medicines interchangeably and to inform them of measures they should take to avoid medication errors.
Estonian: Et on olemas risk ajada Kadcyla ja Herceptin sarnaste nimetustega toimeainete tõttu (trastusumaabemtansiin ja trastusumaab) segi, varustab ettevõte kõik Kadcylat või Herceptini eeldatavasti kasutavad tervishoiutöötajad teabepakmega, et neid ravimeid ei kasutataks üksteise asemel ja et teavitada tervishoiutöötajaid meetmetest, mida nad peavad vale ravimi kasutamise vältimiseks võtma.
English: In one main study, which involved 991 such patients, those treated with Kadcyla lived on average for 9.6 months without their disease getting worse compared with 6.4 months for patients who were treated with two other anti-cancer medicines, capecitabine and lapatanib.
Estonian: Ühes põhiuuringus, milles osales 991 sellist patsienti, oli progresseerumiseta elumus (aeg, mil patsiendid elasid haiguse süvenemiseta) Kadcyla rühmas keskmiselt 9,6 kuud ja patsientidel, keda raviti kahe muu vähiravimi kapetsitabiini ja lapatiniibiga, 6,4 kuud.
English: It is not intended to provide practical advice on how to use Kadcyla.
Estonian: Hindamisaruandes ei anta Kadcyla kasutamise praktilisi nõuandeid.
English: Kadcyla trastuzumab emtansine
Estonian: Kadcyla trastusumaabemtansiin
English: • DM1, a toxic substance that kills cells when they attempt to divide and grow.
Estonian: • DM1 on toksiline aine, mis hävitab jagunevaid ja kasvavaid rakke.
English: What are the risks associated with Kadcyla?
Estonian: Mis riskid Kadcylaga kaasnevad?
English: This is a summary of the European public assessment report (EPAR) for Kadcyla.
Estonian: See on ravimi Kadcyla Euroopa avaliku hindamisaruande kokkuvõte.
English: The most common serious side effects are haemorrhage (bleeding), pyrexia (fever), dyspnoea (difficulty breathing), musculoskeletal pain (pain in muscles and bones), thrombocytopenia (low blood platelet counts), abdominal pain (stomach ache), and vomiting.
Estonian: Kõige sagedamad rasked kõrvalnähud on verejooksud, palavik, düspnoe (raskendatud hinagmine), liigese- ja lihasevalu, trombotsütopeenia (vereliistakute e trombotsüütide vähesus), kõhuvalu ja oksendamine.
English: Kadcyla can only be used when the cancer has been shown to ‘overexpress HER2': this means that the cancer cell produces on its surface large quantities of a protein which stimulates the growth of the cancer cell and is called HER2 (human epidermal growth factor).
Estonian: Kadcylat tohib kasutada üksnes siis, kui vähkkasvaja korral esineb valgu HER2 üleekspressioon: vähirakkude pinnal tekib suures koguses spetsiifilist valku HER2 (inimese epidermaalne kasvufaktor), mis stimuleerib vähirakkude kasvu.
English: Patients treated with Kadcyla also survived for 31 months compared with 25 months for patients treated with capecitabine and lapatinib.
Estonian: Üldine elumus oli Kadcylaga ravitud patsientidel 31 kuud ning kapetsitabiini ja lapatiniibiga ravitud patsientidel 25 kuud.
English: The most common side effects with Kadcyla (which may affect more than 25% of patients) are nausea (feeling sick), fatigue (tiredness) and headache.
Estonian: Kadcyla kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on iiveldus, väsimus ja peavalu.
English: It is used to treat advanced or metastatic breast cancer (cancer that has spread to other parts of the body) in adults who previously received trastuzumab and a taxane (type of cancer medicine).
Estonian: Seda kasutatakse kaugelearenenud või metastaatilise rinnavähi (rinnavähk, mis on levinud organismis ka mujale) raviks täiskasvanutel, kes enne kasutasid trastusumaabi ja taksaani (samuti vähiravimid).
English: By attaching to tubulin in cancer cells, DM1 stops the formation of this skeleton, preventing the division and growth of the cancer cells.
Estonian: Vähirakkudes tubuliiniga seondudes peatab DM1 rakutoese tekkimise ning hoiab ära vähirakkude jagunemise ja kasvamise.
English: Kadcyla has been shown to significantly delay disease getting worse and to prolong survival in patients with advanced and metastatic breast cancer that expressed HER2 and who were previously treated with trastuzumab and a taxane.
Estonian: On tõendatud, et Kadcyla lükkab oluliselt edasi haiguse süvenemist ning pikendab elumust valku HER2 ekspresseeriva kaugelearenenud ja metastaatilise rinnavähiga patsientidel, keda raviti enne trastusumaabi ja taksaaniga.
English: DM1 becomes active once Kadcyla enters the cancer cell.
Estonian: DM1 aktiveerub, kui Kadcyla siseneb vähirakku.
English: For the full list of all side effects reported with Kadcyla, see the package leaflet.
Estonian: Kadcyla kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: How does Kadcyla work?
Estonian: Kuidas Kadcyla toimib?
English: For more information about treatment with Kadcyla, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Kadcylaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Kadcyla, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Kadcyla omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For practical information about using Kadcyla, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Kadcyla kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Kadcyla is a cancer medicine that contains the active substance trastuzumab emtansine.
Estonian: Kadcyla on vähiravim, mis sisaldab toimeainet trastusumaabemtansiini.
English: About a quarter of breast cancers overexpress HER2.
Estonian: HER2 üleekspresseerimist esineb ligikaudu veerandil rinnavähivormidest.
English: • Trastuzumab, a monoclonal antibody (a type of protein) that has been designed to recognise and attach to the protein HER2, which is found in large quantities on the surface of some cancer cells.
Estonian: • Trastusumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära valgu HER2, mida leidub suures koguses teatud vähirakkude pinnal, ja seondub sellega.
English: How is Kadcyla used?
Estonian: Kuidas Kadcylat kasutatakse?
English: The active substance in Kadcyla, trastuzumab emtansine, is made up of two active components which are linked together:
Estonian: Kadcyla toimeaine trastusumaabemtansiin koosneb kahest omavahel seotud toimeainekomponendist:
English: Kadcyla is available as a powder that is made up into a solution for infusion (drip) into a vein.
Estonian: Kadcylat turustatakse pulbrina, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: Kadcyla can only be obtained with a prescription and treatment should be prescribed by a doctor and given under the supervision of a healthcare professional who is experienced in the treatment of cancer patients.
Estonian: Ravi peab määrama arst ja see peab toimuma vähipatsientide ravis kogenud tervishoiutöötaja järelevalve all.
English: What benefits of Kadcyla have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Kadcyla kasulikkus?
English: By attaching to HER2, trastuzumab activates cells of the immune system, which then kill the cancer cells.
Estonian: HER2-ga seondumisel aktiveerib trastusumaab teatud immuunrakke hävitama vähirakke.
English: Trastuzumab also stops HER2 from stimulating the growth of the cancer cells.
Estonian: Trastusumaab peatab ka HER2 vähirakkude kasvu stimuleeriva toime.
English: It attaches to a protein in cells called ‘tubulin', which is important in the formation of the internal ‘skeleton' that cells need to assemble when they divide.
Estonian: Aine seondub rakkudes sisalduva valgu tubuliiniga, millel on oluline osa rakkude jagunemiseks vajaliku raku sisetoese moodustumisel.
English: The CHMP considered that in patients treated with Kadcyla, there was a significant improvement in survival compared with standard therapy.
Estonian: Inimravimite komitee järeldas, et võrreldes standardraviga suurenes Kadcylaga ravitavate patsientide elumus olulisel määral.
English: Further information on Viekirax can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Viekiraxi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Viekirax?
Estonian: Mis meetmed võetakse, et tagada Viekiraxi ohutu ja efektiivne kasutamine?
English: Viekirax received a marketing authorisation valid throughout the EU on 15 January 2015.
Estonian: Viekirax on saanud müügiloa, mis kehtib kogu ELis, 15. jaanuaril 2015.
English: The recommended dose is two tablets taken once a day with food for 8, 12 or 24 weeks.
Estonian: Soovitatav annus on kaks tabletti üks kord ööpäevas koos toiduga 8, 12 või 24 nädala jooksul.
English: What is Viekirax and what is it used for?
Estonian: Mis on Viekirax ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Viekirax are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Viekirax kasutamise kohta pidevat järelevalvet.
English: Viekirax (ombitasvir / paritaprevir / ritonavir)
Estonian: Viekirax (ombitasviir/paritapreviir/ritonaviir)
English: The Agency therefore decided that Viekirax's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Amet otsustas, et Viekiraxi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Viekirax is available as tablets containing 12.5 mg ombitasvir, 75 mg paritaprevir and 50 mg ritonavir.
Estonian: Viekiraxi turustatakse tablettidena, mis sisaldavad 12,5 mg ombitasviiri, 75 mg paritapreviiri ja 50 mg ritonaviiri.
English: Other information about Viekirax
Estonian: Muu teave Viekiraxi kohta
English: This study is being carried out in light of data suggesting that patients treated with these medicines who have had liver cancer could be at risk of their cancer returning early.
Estonian: Seda uuringut peetakse vajalikuks seetõttu, et andmete kohaselt võib asjaomaste ravimitega ravitud patsientidel, kellel on varem olnud maksavähk, olla vähi varajase tagasituleku risk.
English: It must also not be used together with medicines that can raise or lower the levels of Viekirax's active substances in the blood.
Estonian: Ravimit ei tohi kasutada ka koos selliste ravimitega, mis võivad suurendada või vähendada Viekiraxi toimeainete sisaldust veres.
English: What are the risks associated with Viekirax?
Estonian: Mis riskid Viekiraxiga kaasnevad?
English: For more information about using Viekirax, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Viekiraxi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: By blocking these proteins, the medicine prevents the hepatitis C virus from multiplying and infecting new cells.
Estonian: Nende valkude blokeerimisega takistab ravim C-hepatiidi viiruse paljunemist ja uute rakkude nakatamist.
English: The combination of medicines used and the duration of treatment will depend on the genotype of hepatitis C virus infecting the patient, the nature of the patient's liver problems, for example if they have liver cirrhosis (scarring) or their liver is not working properly, and whether they have received previous treatment.
Estonian: Kasutatavate ravimite kombinatsioon ja ravi kestus sõltuvad C-hepatiidi viiruse genotüübist, millega patsient on nakatunud, ja patsiendi maksaprobleemide laadist, näiteks sellest, kas tal on maksatsirroos (maksa sidekoestumine) või maks ei tööta piisavalt hästi, ning sellest, kas patsient on eelnevalt ravi saanud.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Viekirax have also been included in the summary of product characteristics and the package leaflet.
Estonian: Viekiraxi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Side effects reported with Viekirax are carefully evaluated and any necessary action taken to protect patients.
Estonian: Viekiraxi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: The company that markets Viekirax will carry out a study in patients who have had liver cancer to evaluate the risk of liver cancer returning after treatment with direct-acting antivirals such as Viekirax.
Estonian: Viekiraxi turustaja korraldab uuringu patsientidel, kellel on varem olnud maksavähk, et hinnata maksavähi taastumise riski pärast ravi selliste otsese toimega viirusravimitega nagu Viekirax.
English: Almost all the patients with these genotypes treated in studies had the virus cleared from their blood.
Estonian: Peaaegu kõigil nende genotüüpidega patsientidel eemaldati viirus verest.
English: Viekirax is always used in combination with other medicines for chronic hepatitis C, such as dasabuvir and ribavirin.
Estonian: Viekiraxi kasutatakse alati kombinatsioonis muude kroonilise C-hepatiidi ravimitega, nt dasabuviiri ja ribaviriiniga.
English: An additional study showed Viekirax to be effective against genotype 4: when given with ribavirin, Viekirax cleared this genotype from the blood of all the 91 patients infected with it after 12 weeks.
Estonian: Lisauuringus tõendati, et Viekirax on efektiivne 4. genotüübi vastu: ribaviriiniga manustamisel eemaldas Viekirax 12 ravinädala järel selle genotüübi kõigi 91 nakatunud patsiendi verest.
English: It contains 3 active substances: ombitasvir, paritaprevir and ritonavir.
Estonian: Viekirax sisaldab kolme toimeainet: ombitasviiri, paritapreviiri ja ritonaviiri.
English: This slows the removal of paritaprevir from the body, allowing paritaprevir to act against the virus for longer.
Estonian: See suurendab paritapreviiri püsimist organismis ja pikendab paritapreviiri viirusvastast toimet.
English: Several varieties (genotypes) of hepatitis C virus exist, and Viekirax is recommended for patients with virus of genotypes 1a, 1b and 4.
Estonian: C-hepatiidi viirusel on mitu varianti (genotüüpi) ja Viekiraxi soovitatakse patsientidele, kellel on 1a, 1b või 4. genotüübi viirus.
English: The third active substance, ritonavir, does not act directly against hepatitis C virus but it blocks the action of an enzyme called CYP3A that breaks down paritaprevir.
Estonian: Kolmas toimeaine ritonaviir ei toimi otseselt C-hepatiidi viiruse vastu, vaid blokeerib paritapreviiri lõhustava ensüümi CYP3A toime.
English: In 6 initial main studies involving around 2,300 patients infected with hepatitis C virus genotypes 1a or 1b, Viekirax in combination with dasabuvir was effective in clearing the virus from the blood.
Estonian: Esmases kuues põhiuuringus, milles osales ligikaudu 2300 C-hepatiidi viiruse 1a või 1b genotüübiga nakatunud patsienti, oli Viekiraxi ja dasabuviiri kombinatsioonravi efektiivne viiruse eemaldamisel verest.
English: Viekirax is an antiviral medicine used in combination with other medicines to treat adults with chronic (long-term) hepatitis C, an infectious disease of the liver caused by the hepatitis C virus.
Estonian: Viekirax on viirusravim, mida kasutatakse kombinatsioonis muude ravimitega kroonilise (pikaajalise) C-hepatiidi (C-hepatiidi viiruse põhjustatud nakkuslik maksahaigus) raviks täiskasvanutel.
English: For the full list of side effects and restrictions of Viekirax, see the package leaflet.
Estonian: Viekiraxi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The most common side effects with Viekirax in combination with dasabuvir and ribavirin (which may affect more than 1 in 5 people) are tiredness and nausea (feeling sick).
Estonian: Viekiraxi, dasabuviiri ja ribaviriini kombinatsioonravi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on väsimus ja iiveldus.
English: In a seventh study, patients with liver scarring but stable liver function (compensated cirrhosis) who had genotype 1b infection were treated with Exviera and Viekirax without ribavirin and 100% of patients (60 out of 60 patients) had their blood cleared of the virus.
Estonian: Seitsmendas uuringus võtsid maksa sidekoestumisega, ent stabiilse maksatalitlusega (kompenseeritud tsirroos) patsiendid (genotüüp 1b) Exvierat ja Viekiraxi ilma ribaviriinita ning viirus õnnestus verest eemaldada kõigil patsientidel (60 patsienti 60st).
English: The European Medicines Agency noted that Viekirax in combination with other medicines is effective in clearing the hepatitis C virus genotypes 1a, 1b and 4, including in patients with liver scarring.
Estonian: Euroopa Ravimiamet märkis, et kombinatsioonis teiste ravimitega on Viekirax efektiivne C-hepatiidi viiruse 1a, 1b ja 4. genotüübi eemaldamisel organismist, sh maksa sidekoestumisega patsientidel.